Background High-dose chemotherapy with autologous stem-cell transplantation (asct) is an accepted part of
example, high-dose cyclophosphamide). In some clinical scenarios, patients are not able to undergo mobilization with chemotherapy and g-csf, and such patients can be at higher risk of failing mobilization. Other risk factors for failing mobilization include prior treatment with multiple lines of chemotherapy or purine analogues, radiation to bone marrow-containing areas, and patient age; however, those factors remain poorly defined for the most part and largely consensus-driven 1 .
Plerixafor is a novel mobilization agent and a bicyclam derivative that binds with high affinity to the human C-X-C chemokine receptor type 4 receptor and disrupts interactions with its cognate ligand stromal cell-derived factor 1α. Interruption of that receptor-ligand interaction results in mobilization of CD34+ hematopoietic stem cells to the peripheral blood, where they can be collected via apheresis. Plerixafor is absorbed quickly after a subcutaneous injection and, at the recommended dose of 0.24 mg/kg, provides a sustained increase in circulating CD34+ cells for 10-18 hours. Dose adjustments are not needed for patients with hepatic or renal insufficiency, and in general, the agent is well tolerated. In December 2011, Health Canada approval was granted for the use of plerixafor with g-csf in stemcell mobilization for patients with nhl or myeloma. In Ontario, plerixafor is currently covered for use with g-csf in patients with nhl or myeloma who have suboptimal peripheral blood CD34+ cell counts after at least 4 days of g-csf (CD34+ count < 10/μL), or who have less than half the required CD34+ cells after 1 apheresis procedure, or who have failed a previous apheresis attempt.
To make recommendations for clinical practice and to assist Cancer Care Ontario in decision-making with respect to intervention with plerixafor, the Working Group of the Stem Cell Transplant Steering Committee developed the present recommendation report. Based on the objectives of the guideline, the members of the Working Group derived the research questions as outlined later in the report.
METHODS
This recommendation report, produced by the Program in Evidence-Based Care (pebc) and approved by the Stem Cell Transplant Steering Committee of Cancer Care Ontario, was developed through a systematic review of the available evidence using the methods of the practice guidelines development cycle 2, 3 . The pebc is editorially independent of the Ontario Ministry of Health and Long-Term Care.
This evidence review was conducted in 3 planned stages, including a search for existing guidelines followed by a search for systematic reviews and primary literature.
Literature Search Strategy
Before any search for systematic reviews or primary literature, an electronic search for existing guidelines concerning the efficacy of plerixafor was conducted using the electronic databases medline (Ovid) and embase (Ovid) and the Standards and Guidelines Evidence (sage) directory of cancer guidelines. The goal was to identify existing guidelines for adaptation or endorsement so as to avoid duplication of guideline development efforts across jurisdictions. Only guidelines published in English and after 2010 were considered and evaluated for quality using the agree ii instrument 4 . In addition, the Cochrane Database of Systematic Reviews and the medline (Ovid) and embase (Ovid) databases were searched from January 2009 to April 2014. Any systematic reviews identified were assessed for quality using amstar 5 ; the results of the amstar assessment were used to determine the inclusion of existing systematic reviews as part of the evidence base.
Assuming that no existing guidelines or systematic reviews were identified, a systematic review of the primary literature was also planned. If a suitable guideline or systematic review had been found, a systematic review of the primary literature would be conducted from the date of the reported search, solely to update the evidence from the existing guidelines or systematic reviews.
In April 2014, the medline (Ovid; 1996 through 18 April 2014) and embase (Ovid; 1996 through Week 16, 2014) databases were searched for primary literature; the search was updated in March 2015. The search strategy included a logical combination of terms for the condition (stem-cell transplantation), the intervention (plerixafor), and studies of interest (systematic reviews, clinical trials, nonrandomized studies with an appropriate control group). Relevant articles were reviewed by 2 reviewers (CTK, NPV), and the reference lists from those sources were searched for additional trials. A data audit procedure was conducted by an independent individual (Kristy Yiu) to verify the accuracy of the information obtained from the included studies.
RESULTS

Literature Search
Twenty-two studies assessing the efficacy and safety of plerixafor for autologous stem-cell mobilization and transplantation were retained: two randomized controlled trials (rcts) 6, 7 , five nonrandomized controlled trials [8] [9] [10] [11] [12] , three retrospective cohort studies with a contemporaneous control arm [13] [14] [15] , and twelve single-arm studies [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] .
Quality was assessed according to the criteria described in the Methods section. Table i provides details about patient selection criteria, peripheral blood stem-cell mobilization regimen, sample size, and reported outcomes.
The two rcts reported by DiPersio et al. 6, 7 were phase iii, multicentre, double-blind trials with random allocation schemes and involved patients with nhl or mm. In the lymphoma study 6 , patients were randomized 1:1, but other details were not reported. In the myeloma study 7 , patients were stratified by study centre, baseline platelet count, and type of transplantation planned.
The five nonrandomized controlled trials [8] [9] [10] [11] [12] included fully described the inclusion and exclusion criteria, mobilization protocol, and outcomes of interest. Four of the studies compared outcomes with matched historical controls mobilized using a therapy that did not include plerixafor 8, 9, 11, 12 .
The twelve single-arm trials [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] were included in the review to inform recommendations both for patients failing mobilization before asct and for patients failing a prior mobilization attempt. In all those studies, the patients were fully described and were representative of the population of interest. In all studies, the mobilization regimen was consistent with the regimen that would be used in Ontario clinical practice. Eight of the studies 17, 18, [20] [21] [22] [23] 26, 28 included patients enrolled in a European compassionate-use program (cup) for patients who had previously failed conventional mobilization attempts. The inclusion and exclusion criteria were fully described for all those studies. The remaining three trials were independent studies conducted in education centres in Finland 24 and the United States 25, 27 . Selection of patients was based on low peripheral blood CD34+ cell count or poor yield in the 1st apheresis procedure. The mobilization regimens were well described, as were the outcomes of median collection, percentage of patients meeting the primary endpoint of achieving the CD34+ cell target, and number of apheresis procedures. The reported outcomes included the proportion of patients reaching at least 2×10 6 CD34+ cells per kilogram, median CD34+ cell collection and range, and number of apheresis procedures. Some studies reported the number and proportion of patients who proceeded to asct and who survived to the 12-month follow-up.
Overall, the quality assessment found all of the foregoing plerixafor trials to be of acceptable quality given the nature of their study designs.
Outcomes
Patients Not Previously Mobilized
Table ii summarizes results in patients in whom mobilization had not previously been attempted.
CD34+ Cells Collected:
The two rcts reported by DiPersio et al. 6 .7 detected a statistically significant difference in mobilization rates favouring regimens using plerixafor compared with conventional mobilization treatment, both for patients with nhl (59.3% vs. 19.6%, p < 0.001, and 86.7% vs. 47.3%, p < 0.001 for patients collecting ≥5×10 6 and ≥2×10 6 CD34+ cells respectively) 6 and for patients with mm (71.6% vs. 34.4%, p < 0.001 for patients collecting ≥6×10 6 /kg CD34+ cells) 7 . Similarly, four nonrandomized trials using historical controls 8, 9, 11, 12 reported a statistically significant increase in the proportion of patients collecting CD34+ cells in favour of mobilization therapies using plerixafor compared with conventional treatment (68% -94% vs. 15%-76% respectively). The two rcts reported by DiPersio et al. 6, 7 are the current best evidence from research concerning the safety and efficacy of plerixafor for autologous stem-cell mobilization and transplantation, given that rcts are the most rigorous way of determining evidence of cause and effect.
Apheresis Procedures: One rct reported by DiPersio et al. 7 and two trials with historical controls demonstrated the ability of regimens with plerixafor, compared with conventional mobilization therapies, to significantly reduce the number of apheresis procedures required to collect the target number of CD34+ cells (1 vs. 4, p < 0.001) 7 , (1.61 vs. 1.43, p = 0.04) 11 , and (3 vs. 2, p < 0.0001) 14 . Two trials with historical controls reported no differences between groups with respect to the time of collection 9, 12 . Centres participating in the compassionate use program for plerixafor were also able to combine chemotherapy with G-CSF and plerixafor for mobilization.
Pts = patients; G-CSF = granulocyte colony-stimulating factor; NHL = non-Hodgkin lymphoma; SCT = stem-cell transplantation; MM = multiple myeloma; HD = Hodgkin disease; AUC = area under the curve. 12 reported a nonsignificant difference between groups (10.7 for plerixafor vs. 11.6 for conventional therapy, p = 0.5).
DiPersio et al. 6 reported a higher number of CD34+ cells associated with a plerixafor mobilization strategy (5.69 vs. 1.98), but statistical significance was not reported.
Proportion of Patients Who Proceed to ASCT:
Only the rct reported by DiPersio et al. 6 detected a statistically significant difference in the proportion of patients undergoing asct that favoured plerixafor regimens over mobilization therapy using g-csf alone (90% vs. 55.4%, p < 0.001). None of the other comparative studies reported statistically significant differences between groups 7-9,11,12,29 .
Survival Rate After ASCT:
Only two studies, the rcts reported by DiPersio et al. 6, 7 , reported the 12-month survival rate after asct for both groups (mobilization therapy using g-csf alone, and with added plerixafor), but the statistical difference between the rates was not reported. None of the other studies reported this outcome 8, 9, 11, 12, 14, 29 . Table iii summarizes results in patients in whom mobilization had been attempted, but with poor response.
Patients Who Seem to Mobilize Poorly to Current Regimens
CD34+ Cells Collected:
An "on demand" prospective study by Milone et al. 11 assessed the efficacy of plerixafor in patients who mobilize poorly. In patients predicted to fail harvest, those authors detected a statistically significant increase in CD34+ harvest rates associated with the use of plerixafor compared with no plerixafor (60% vs. 0%, p = 0.01). Similarly, a retrospective study comparing g-csf (filgrastim) plus plerixafor with other regimens after primary mobilization failure 15 detected a statistically significant increase in favour of plerixafor in the number of CD34+ cells collected in 1 apheresis procedure after 2nd mobilization (37%, 0%, and 2% for g-csf plus plerixafor, g-csf plus chemotherapy, and g-csf plus granulocyte-macrophage colony-stimulating factor respectively; p < 0.0001). Two single centres evaluated the efficacy of the pre-emptive use of plerixafor after chemomobilization with g-csf in patients who seem to mobilize poorly and reported that the minimum CD34+ collection target was achieved by 80% 24 and 97% 27 of their patients.
Peripheral Blood CD34+ Cell Count and Number of Apheresis Procedures:
Two comparative studies reported a statistically significant increase in the number of CD34+ cells collected (given here as millions per kilogram body weight) and in the median number of apheresis procedures for patients who received plerixafor compared with patients who received other regimens after primary mobilization failure 10, 15 . In the retrospective comparative study reported by
Perkins et al. 15 , the median number of CD34+ cells collected was reported to be 2.1 in 1 apheresis procedure for g-csf plus plerixafor, 1.19 in 2 apheresis procedures for g-csf plus chemotherapy, and 1.44 in 2 apheresis procedures for g-csf plus granulocyte-macrophage colony-stimulating factor (p = 0.01 for median number of CD34+ cells collected and p = 0.04 for median number of apheresis procedures). The study by Hundemer et al. 10 , in which data were matched with a historical control group on the basis of poor stemcell yield in the first apheresis session, reported a median CD34+ collection of 4.9 in 2 apheresis procedures with plerixafor and 3.7 in 4 apheresis procedures with g-csf (p = 0.01). The comparative study reported by Cheng et al. 13 reported a median CD34+ collection of 8.5 for patients receiving plerixafor compared with 4.8 for patients not receiving plerixafor (p = 0.003), but the median number of apheresis procedures was not reported. Three single-arm studies 16, 24, 27 reported median numbers of CD34+ cells of 2.9, 5.08, and 3.42 with a median number of apheresis procedures of 1 (range: 1-3), 5 (range: 1-10), and 2 (range: 1-4) respectively.
Proportion of Patients Who Proceed to ASCT:
Only the comparative study reported by Perkins et al. 15 reported a statistically significant difference in the proportion of patients who underwent transplantation favouring plerixafor compared with other regimens after primary mobilization failure (84% for g-csf plus plerixafor, 53% for g-csf plus chemotherapy, and 84% for g-csf plus granulocytemacrophage colony-stimulating factor; p = 0.03). Cheng et al. 13 reported that all patients (100%) in the group receiving plerixafor and 83% of patients in the group not receiving plerixafor underwent transplantation, but statistical significance was not reported. The single-arm study by Smith et al. 27 reported that, among patients who seem to mobilize poorly and who received just-in-time rescue plerixafor plus chemotherapy and g-csf, 95% proceeded to asct. No other studies reported that outcome.
Survival Rate After ASCT:
None of the studies evaluating the efficacy of plerixafor in patients failing mobilization (those who seemed to mobilize poorly) reported on survival rate after asct. 
Patients Who Failed a Prior Mobilization Regimen
CD34+ Cells Collected:
Eleven studies reported on the efficacy of plerixafor in patients who mobilize poorly. One comparative study reported by DiPersio et al. 6 reported that, among patients with nhl who failed prior mobilization regimens with g-csf plus plerixafor and g-csf plus placebo, 40% and 64% were able to achieve at least the minimum collection target. Those authors also reported that all patients with mm who failed previous mobilization attempts (7 of 7) were able to achieve the minimum collection target of 2×10 6 /kg CD34+ cells 7 . An additional singlearm study reported by Lor et al. 25 assessed the efficacy of plerixafor plus g-csf (filgrastim) as second-line therapy for patients who failed to respond to g-csf (filgrastim) plus TABLE III Summary of outcomes reported by studies assessing the efficacy of plerixafor in patients who seem to mobilize poorly to current regimens (low peripheral blood CD34+ collected before first apheresis procedure or inadequate first-day apheresis collection) chemotherapy (cyclophosphamide) as the initial mobilization strategy. Plerixafor plus g-csf successfully mobilized at least the minimum CD34+ collection target in 84% of the patients (100% of patients with mm and 67% of patients with nhl). The study reported by Calandra et al. 20 reported that the success of patients collecting ≥2×10 6 /kg CD34+ cells exceeded 66% overall and was higher for patients with Hodgkin disease (77%) and mm (71%), but not for patients with non-Hodgkin disease (60%).
Reference
The remaining seven studies reported results from 13 European countries (Austria, Belgium, Croatia, Czech Republic, France, Germany, Hungary, Italy, Poland, Portugal, Slovakia, Spain, and the United Kingdom) that enrolled patients in a compassionate use program that provided plerixafor to patients who had failed prior mobilization attempts [17] [18] [19] [21] [22] [23] 26 . In a subgroup analysis from the European Consortium of Stem Cell Mobilization, Hubel et al. 22 reported results for 580 patients enrolled in European cups. In a second report, the same authors 23 presented results for a subgroup of 60 patients from 23 centres in Germany who participated in a cup. Basak et al. 19 reported results for a cohort of 61 patients from 11 Polish centres and for a subgroup of 76 patients from Poland with mm who also participated in a cup 18 . Duarte et al. 21 reported outcomes for a subgroup of 56 patients from 15 participating centres in Spain and the United Kingdom. The study reported by Arcaini et al. 17 involved 35 patients from 7 Italian centres participating in a cup. Malard et al. 26 reported outcomes for 83 patients enrolled in a cup who had previously been treated with fludarabine or lenalidomide. Overall, success in collecting 2×10 6 /kg CD34+ cells for patients who participated in European cups was significantly higher in those with mm than with nhl (82% vs. 65%, p < 0.0001) and also in patients with hl than in patients with nhl (82% vs. 65%, p = 0.017) 22 . For the remaining studies, the rates of adequate CD34+ cell collection ranged from a low of 37% in patients with nhl and patients with hl combined 17 to a high of 100% in patients with Hodgkin disease 23 .
Peripheral Blood CD34+ Cell Count and Number of Apheresis Procedures:
Results from a subgroup analysis of the European Consortium of Stem Cell Mobilization (580 patients) found that, overall, the CD34+ collection yield (given here as millions per kilogram body weight) was significantly higher in patients with mm than in patients with nhl (3.60 vs. 2.56, p < 0.0001) and also in patients with hl than in patients with nhl (3.14 vs. 2.56, p = 0.013). No differences between the groups in the time of collection were detected 22 . Similarly, Lor et al. 25 and Calandra et al. 20 reported higher CD34+ cell collection yields in patients with mm than in patients with nhl, but statistical significance was not reported. No significant differences between groups in the time of collection were reported by those authors.
Proportion of Patients Who Proceed to ASCT:
DiPersio et al. found that 84% (52 of 62) of patients with nhl 6 and 100% (7 of 7) of patients with mm 7 who had failed a prior mobilization regimen underwent asct after remobilization with plerixafor. Calandra et al. 20 reported that more than 70% of patients who had failed prior mobilization regimens proceeded to asct after having been remobilized with plerixafor. Five additional studies reported asct rates ranging from a low of 17% 17 to a high of 88% 23 .
Survival Rate After ASCT: Only DiPersio et al. reported a 12-month survival rate after remobilization with plerixafor. That rate was 86% in patients with nhl and 100% in those with mm 6, 7 . None of the other studies reported on this outcome 13, [17] [18] [19] [20] [21] [22] [23] 25, 26 .
DISCUSSION
Plerixafor is a novel mobilization agent that has been approved for use in Canada with g-csf in the mobilization of stem cells in patients with nhl or mm who require high-dose chemotherapy and asct. The available studies on the use plerixafor for initial mobilization could not answer the question of how mobilization with plerixafor plus g-csf compares with mobilization using chemotherapy plus g-csf. Mobilization with plerixafor plus g-csf appeared to be superior to mobilization with g-csf alone in patients with lymphoma, but not necessarily superior in patients with myeloma.
Administering chemotherapy for mobilization can introduce additional adverse effects that could contribute to morbidity and might delay patients in reaching transplantation, but the available studies were not designed to answer that type of question (a focus on health care utilization or trade-offs). We therefore felt that the standard mobilization of chemotherapy plus g-csf was a reasonable practice to continue, but that in patients with lymphoma who could not receive chemotherapy plus g-csf (because, for example, of renal insufficiency), an initial mobilization with plerixafor plus g-csf appears to be preferred and is therefore recommended.
The use of plerixafor plus g-csf "on demand" for patients who appear to be mobilizing poorly was felt to be a useful strategy to maximize the benefits of plerixafor and to minimize the risk of requiring remobilization, therefore allowing patients to proceed to transplantation in a timely fashion. It is accepted that a uniform definition of a poor mobilizer might not have yet been developed, but commonly used measurements of peripheral blood CD34+ cells or stem-cell yields on the 1st day of apheresis were felt to be quite reasonable.
The use of plerixafor plus g-csf for remobilization is completely endorsed despite the nature of the available literature. Patients who are candidates for asct have no other option than to try to reach transplantation and therefore the use of plerixafor plus g-csf is strongly recommended. With many health care centres opting to use plerixafor plus g-csf "on demand" in poor mobilizers, the number of patients requiring remobilization is expected to decline over time.
The current Health Canada recommendation is to use plerixafor plus g-csf in patients with nhl or myeloma. The biologic activity of the drug and the similarities of the stem-cell mobilization process in hl and germ-cell tumours are expected to resemble the activity and mobilization process in nhl and myeloma. Some studies did include some patients with hl and other indications. We therefore felt that the benefits of plerixafor could be generalized to patients with hl or germ-cell tumours and that plerixafor should be used for those patients in a way similar to that for patients with nhl or myeloma.
REVIEW PROCESS
The health research methodologist (NPV) in collaboration with the lead author (CTK) wrote the initial recommendations and qualifying statement pertaining to the benefit associated with the use of plerixafor for hematopoietic stem-cell mobilization and collection in patients considered for asct. That report was circulated to the members of the Stem Cell Transplant Working Group and was discussed during a teleconference, after which the draft recommendations were generated. The ensuing recommendation report was reviewed by the pebc's Report Approval Panel (scientific director, the pebc assistant director, and two health research methodologists) to ensure that the guideline development was methodologically rigorous and that the evidence-based recommendations are indeed supported by the evidence in a transparent way. After internal review, the refined report was presented to the entire Stem Cell Transplant Steering Committee to ensure the clinical relevance and utility of the recommendations, and to obtain final approval.
Practice guidelines and recommendation reports developed by the pebc are reviewed and updated as needed. Please visit the Cancer Care Ontario Web site (http://www.cancercare.on.ca) for the full report and subsequent updates.
PRACTICE GUIDELINE
Evidence from a systematic search of the primary literature, consensus of expert opinion, feedback obtained through the review process, and a final approval given by the Stem Cell Transplant Steering Committee and the pebc's Report Approval Panel collectively form the basis of this recommendation report, completed in September 2015.
Target Population
The target population for this guideline includes all adult patients considered for asct and meeting one of the following criteria:
■ Not previously mobilized (that is, upfront mobilization in naïve patients who might or might not be at risk of being poor mobilizers) ■ Failing initial mobilization (based on peripheral blood CD34+ cell count before 1st day of apheresis, or total number of CD34+ cells collected on the 1st day of apheresis) ■ Failed a prior mobilization attempt (that is, poor mobilizers)
Recommendation 1
■ Adding plerixafor to g-csf is an option for final mobilization in patients with nhl or mm who are eligible for asct when chemotherapy cannot be used and only g-csf mobilization is available.
This recommendation is based on the results of five studies involving patients with nhl, relapsed or refractory hl, and mm who received g-csf either alone or as part of the initial mobilization therapy. Two randomized controlled trials 6, 7 detected that, in patients with nhl or mm, the addition of plerixafor to g-csf resulted in a greater yield of stem cells and fewer days of apheresis, and allowed more patients to proceed to asct. Likewise, three nonrandomized trials with historical controls 8, 11, 14 reported significantly higher response rates in favour of adding plerixafor.
Qualifying Statements
■ The available evidence used patients receiving g-csf alone as the control group. Therefore, the option of plerixafor as an upfront therapy is specific to patients undergoing initial mobilization with g-csf and without chemotherapy. ■ The evidence is insufficient to support the addition of plerixafor to g-csf after chemotherapy as initial mobilization in patients eligible for asct. ■ Adding plerixafor to g-csf for initial mobilization therapy when chemotherapy cannot be used and only g-csf mobilization is available is an option regardless of the underlying malignancy [that is, in plasma cell dyscrasias (myeloma, amyloidosis), nhl and hl, and germ-cell tumours]. ■ Using plerixafor upfront with g-csf might not be costeffective (that strategy was not examined in the present review), particularly if compared with the plerixafor "on demand" strategy already recommended. The members of the Working Group therefore determined that, rather than making upfront use a strict recommendation for routine use, such use might be an option when compared with the use of g-csf alone.
Recommendation 2
■ For patients with low peripheral blood CD34+ cell counts (for example, <10/μL) at the anticipated time of stem-cell harvesting or with an inadequate 1st-day apheresis collection, it is recommended that plerixafor be added to the mobilization regimen to maximize stem-cell collection and to prevent the need for remobilization.
This recommendation is supported by seven nonrandomized studies that reported a variety of outcomes, including number of stem cells collected and number of days of apheresis 10, 11, 13, 15, 16, 24, 27 . In general, those studies detected that a better mobilization response is achieved in patients failing their first mobilization attempt when plerixafor is added to their existing mobilization regimens. Additionally, three studies demonstrated that a significant proportion of patients were able to proceed to asct with plerixafor 13, 15, 27 .
Qualifying Statements
■ Poor mobilization was variably defined in the applicable studies, but fewer than 10/μL CD34+ cells in peripheral blood is a commonly used criterion. Historical data and consensus opinion have identified that the likelihood of successful stem-cell harvest is low for patients with fewer than 10/μL CD34+ cells in peripheral blood. In such patients, who appear to be at high risk of failing initial mobilization, a strategy of on-demand plerixafor could prevent the need for remobilization and therefore minimize further delays in proceeding to asct. ■ Plerixafor is recommended regardless of the underlying malignancy [that is, plasma cell dyscrasias (myeloma, amyloidosis), nhl and hl, germ-cell tumours].
Recommendation 3
■ For patients in whom a previous mobilization attempt has failed, remobilization with g-csf and plerixafor with or without chemotherapy is recommended.
Several single-arm studies detected that, with plerixafor and g-csf with or without chemotherapy, a significant proportion of patients can still collect enough CD34+ cells to proceed to asct 6, 7, 13, [17] [18] [19] [20] [21] [22] [23] 25, 26 .
Qualifying Statement
■ The definition of failed mobilization in this group of studies is variable and includes patients who did not attain at least the minimum number of CD34+ cells or patients who had low numbers of circulating CD34+ cells before apheresis. It is recognized that every attempt should be made to collect enough CD34+ cells in such patients to allow them to proceed to definitive therapy with asct. ■ Plerixafor is recommended regardless of the underlying malignancy [that is, plasma cell dyscrasias (myeloma, amyloidosis), nhl and hl, germ-cell tumours].
